Investment analysts at UBS AG hoisted their price objective on shares of Cubist Pharmaceuticals (NASDAQ:CBST) from $61.00 to $70.00 in a note issued to investors on Wednesday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock. UBS AG’s price target suggests a potential upside of 12.31% from the stock’s previous close.
henhill69
Check out the details of CBST's Planned Acquisitions of OPTR & TSRX @ http://stks.co/adA3
2013-08-02 12:46